-
Je něco špatně v tomto záznamu ?
Fenofibrate Attenuates Malignant Hypertension by Suppression of the Renin-angiotensin System: A Study in Cyp1a1-Ren-2 Transgenic Rats
Š. Jíchová, Š. Doleželová, L. Kopkan, E. Kompanowska-Jezierska, J. Sadowski, L. Červenka,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
- MeSH
- aktivace transkripce MeSH
- cytochrom P-450 CYP1A1 genetika MeSH
- cytochrom P450 CYP4A metabolismus MeSH
- fenofibrát farmakologie terapeutické užití MeSH
- hodnoty glomerulární filtrace účinky léků MeSH
- homeostáza účinky léků MeSH
- hypertenze maligní chemicky indukované farmakoterapie MeSH
- indoly MeSH
- krevní tlak MeSH
- kyseliny hydroxyeikosatetraenové metabolismus MeSH
- ledviny metabolismus MeSH
- natriuréza účinky léků MeSH
- potkani transgenní MeSH
- renální oběh účinky léků MeSH
- renin-angiotensin systém účinky léků MeSH
- renin genetika MeSH
- zvířata MeSH
- Check Tag
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Malignant hypertension is a life-threatening condition, and its pathophysiology is still poorly understood. The present study was designed to evaluate the role of interaction of the renin-angiotensin system with 20-hydroxyeicosatetraenoic acid (20-HETE), a product of cytochrome P450 (CYP)-dependent ω-hydroxylase pathway, in the pathophysiology of angiotensin II (ANG II)-dependent malignant hypertension in Cyp1a1-Ren-2 transgenic rats. METHODS: Malignant hypertension was induced by 12 days׳ dietary administration of 0.3 % indole-3-carbinol (I3C), a natural xenobiotic that activates a mouse renin gene. We hypothesized that chronic administration of fenofibrate, 190mg/kg body weight, a lipid-lowering drug, should increase renal production of 20-HETE, a tubular transport inhibitor; an expected increase in sodium excretion would oppose the development of ANG II-dependent malignant hypertension. Blood pressure was monitored by radiotelemetry, and at the end of the experiment rats were prepared for renal functional studies to evaluate in vivo the pressure-natriuresis relationship in response to stepwise reductions in renal arterial pressure (RAP). RESULTS: In I3C-induced rats, the treatment with fenofibrate significantly attenuated hypertension and improved the slope of the pressure-natriuresis relationship. Although fenofibrate treatment increased kidney gene and protein expression of CYP4A1, a major isoform responsible for 20-HETE formation, it did not increase renal 20-HETE concentration. On the contrary, fenofibrate treatment significantly suppressed renin gene expression, plasma renin activity and plasma and kidney ANG II levels. CONCLUSIONS: Fenofibrate treatment significantly attenuated the course of malignant hypertension in I3C-induced CYP1a1-Ren-2 transgenic rats, and the mechanism responsible for antihypertensive action was fenofibrate-induced suppression of renin-angiotensin system activity.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17023455
- 003
- CZ-PrNML
- 005
- 20180930132909.0
- 007
- ta
- 008
- 170720s2016 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.amjms.2016.09.008 $2 doi
- 035 __
- $a (PubMed)27916218
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Jíchová, Šárka $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Department of Pathophysiology, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
- 245 10
- $a Fenofibrate Attenuates Malignant Hypertension by Suppression of the Renin-angiotensin System: A Study in Cyp1a1-Ren-2 Transgenic Rats / $c Š. Jíchová, Š. Doleželová, L. Kopkan, E. Kompanowska-Jezierska, J. Sadowski, L. Červenka,
- 520 9_
- $a BACKGROUND: Malignant hypertension is a life-threatening condition, and its pathophysiology is still poorly understood. The present study was designed to evaluate the role of interaction of the renin-angiotensin system with 20-hydroxyeicosatetraenoic acid (20-HETE), a product of cytochrome P450 (CYP)-dependent ω-hydroxylase pathway, in the pathophysiology of angiotensin II (ANG II)-dependent malignant hypertension in Cyp1a1-Ren-2 transgenic rats. METHODS: Malignant hypertension was induced by 12 days׳ dietary administration of 0.3 % indole-3-carbinol (I3C), a natural xenobiotic that activates a mouse renin gene. We hypothesized that chronic administration of fenofibrate, 190mg/kg body weight, a lipid-lowering drug, should increase renal production of 20-HETE, a tubular transport inhibitor; an expected increase in sodium excretion would oppose the development of ANG II-dependent malignant hypertension. Blood pressure was monitored by radiotelemetry, and at the end of the experiment rats were prepared for renal functional studies to evaluate in vivo the pressure-natriuresis relationship in response to stepwise reductions in renal arterial pressure (RAP). RESULTS: In I3C-induced rats, the treatment with fenofibrate significantly attenuated hypertension and improved the slope of the pressure-natriuresis relationship. Although fenofibrate treatment increased kidney gene and protein expression of CYP4A1, a major isoform responsible for 20-HETE formation, it did not increase renal 20-HETE concentration. On the contrary, fenofibrate treatment significantly suppressed renin gene expression, plasma renin activity and plasma and kidney ANG II levels. CONCLUSIONS: Fenofibrate treatment significantly attenuated the course of malignant hypertension in I3C-induced CYP1a1-Ren-2 transgenic rats, and the mechanism responsible for antihypertensive action was fenofibrate-induced suppression of renin-angiotensin system activity.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a krevní tlak $7 D001794
- 650 _2
- $a cytochrom P-450 CYP1A1 $x genetika $7 D019363
- 650 _2
- $a cytochrom P450 CYP4A $x metabolismus $7 D042926
- 650 _2
- $a fenofibrát $x farmakologie $x terapeutické užití $7 D011345
- 650 _2
- $a hodnoty glomerulární filtrace $x účinky léků $7 D005919
- 650 _2
- $a homeostáza $x účinky léků $7 D006706
- 650 _2
- $a kyseliny hydroxyeikosatetraenové $x metabolismus $7 D006893
- 650 _2
- $a hypertenze maligní $x chemicky indukované $x farmakoterapie $7 D006974
- 650 _2
- $a indoly $7 D007211
- 650 _2
- $a ledviny $x metabolismus $7 D007668
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a natriuréza $x účinky léků $7 D009318
- 650 _2
- $a potkani transgenní $7 D055647
- 650 _2
- $a renální oběh $x účinky léků $7 D012079
- 650 _2
- $a renin $x genetika $7 D012083
- 650 _2
- $a renin-angiotensin systém $x účinky léků $7 D012084
- 650 _2
- $a aktivace transkripce $7 D015533
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Doleželová, Šárka $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. $7 xx0227631
- 700 1_
- $a Kopkan, Libor $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- 700 1_
- $a Kompanowska-Jezierska, Elzbieta $u Department of Renal and Body Fluid Physiology, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland.
- 700 1_
- $a Sadowski, Janusz $u Department of Renal and Body Fluid Physiology, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland.
- 700 1_
- $a Červenka, Luděk $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Department of Pathophysiology, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic. Electronic address: luce@medicon.cz.
- 773 0_
- $w MED00000305 $t The American journal of the medical sciences $x 1538-2990 $g Roč. 352, č. 6 (2016), s. 618-630
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27916218 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170720 $b ABA008
- 991 __
- $a 20180930133353 $b ABA008
- 999 __
- $a ok $b bmc $g 1239136 $s 984368
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 352 $c 6 $d 618-630 $e 20160927 $i 1538-2990 $m The American journal of the medical sciences $n Am J Med Sci $x MED00000305
- LZP __
- $a Pubmed-20170720